These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 27873576)

  • 1. Assessment of combination therapy by time kill curve analysis and chequerboard assay for treatment of multi-drug resistant Pseudomonas aeruginosa isolates.
    Rizvi M; Ahmed J; Khan F; Shukla I; Malik A
    J Glob Antimicrob Resist; 2013 Jun; 1(2):103-108. PubMed ID: 27873576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa.
    Rizvi M; Ahmad J; Khan F; Shukla I; Malik A; Sami H
    Australas Med J; 2015; 8(1):1-6. PubMed ID: 25848402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
    Dawis MA; Isenberg HD; France KA; Jenkins SG
    J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.
    Drago L; De Vecchi E; Nicola L; Colombo A; Guerra A; Gismondo MR
    Chemotherapy; 2004 Oct; 50(4):202-10. PubMed ID: 15452399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
    Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa.
    Oie S; Uematsu T; Sawa A; Mizuno H; Tomita M; Ishida S; Okano Y; Kamiya A
    J Antimicrob Chemother; 2003 Dec; 52(6):911-4. PubMed ID: 14585851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
    Yasmin F; Akhtar N; Hameed A
    Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.
    Petersen PJ; Labthavikul P; Jones CH; Bradford PA
    J Antimicrob Chemother; 2006 Mar; 57(3):573-6. PubMed ID: 16431863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
    Pankey GA; Ashcraft DS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2959-64. PubMed ID: 15980375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
    Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
    J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India.
    Javiya VA; Ghatak SB; Patel KR; Patel JA
    Indian J Pharmacol; 2008 Oct; 40(5):230-4. PubMed ID: 20040963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa.
    Santos DA; Nascimento MM; Vitali LH; Martinez R
    Rev Soc Bras Med Trop; 2013; 46(3):299-303. PubMed ID: 23856877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
    Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
    J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
    Drago L; De Vecchi E; Nicola L; Gismondo MR
    BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic fingerprinting and antimicrobial susceptibility profiles of Pseudomonas aeruginosa hospital isolates in Malaysia.
    Lim KT; Yasin RM; Yeo CC; Puthucheary SD; Balan G; Maning N; Wahab ZA; Ismail N; Tan EA; Mustaffa A; Thong KL
    J Microbiol Immunol Infect; 2009 Jun; 42(3):197-209. PubMed ID: 19812853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.
    Landman D; Bratu S; Alam M; Quale J
    J Antimicrob Chemother; 2005 Jun; 55(6):954-7. PubMed ID: 15883174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
    West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.